Form 4 for TXMD TherapeuticsMD, Inc.
Accepted 2023-01-30 00:00:00 ET · period of report 2023-01-26 · accession 0001209191-23-005554 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2023-01-30 | 2023-01-26 | TXMD | Donegan Michael C | Prin. Fin, Acctg. Off | M - OptEx | $0.00 | +5,940 | 13.6K | +78% | $0 |
| DM | 2023-01-30 | 2023-01-26+ | TXMD | Donegan Michael C | Prin. Fin, Acctg. Off | S - Sale+OE | $5.08 | -1,697 | 11.9K | -13% | -$8,621 |
| DM | 2023-01-30 | 2023-01-26 | TXMD | Donegan Michael C | Prin. Fin, Acctg. Off | M - OptEx | $0.00 | -5,940 | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-01-26 | M | A | 2,400 | $0.00 | 12,410 | D | — | — | (F1) Each performance stock unit ("PSU") represents a contingent right to receive one share of issuer common stock upon settlement. On January 26, 2023, the reporting person received 5,940 shares of issuer common stock in settlement of performance stock units (PSUs). |
| 2 | Common | Common Stock | 2023-01-26 | M | A | 2,400 | $0.00 | 10,010 | D | — | — | (F1) Each performance stock unit ("PSU") represents a contingent right to receive one share of issuer common stock upon settlement. On January 26, 2023, the reporting person received 5,940 shares of issuer common stock in settlement of performance stock units (PSUs). |
| 3 | Common | Common Stock | 2023-01-26 | S | D | 1,648 | $5.08 | 11,902 | D | — | — | (F3) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.01 through $5.17, inclusive. The reporting person undertakes to provide to TherapeuticsMD, Inc., any security holder of TherapeuticsMD, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth. |
| 4 | Common | Common Stock | 2023-01-26 | M | A | 1,140 | $0.00 | 13,550 | D | — | — | (F1) Each performance stock unit ("PSU") represents a contingent right to receive one share of issuer common stock upon settlement. On January 26, 2023, the reporting person received 5,940 shares of issuer common stock in settlement of performance stock units (PSUs). |
| 5 | Common | Common Stock | 2023-01-27 | S | D | 49 | $5.09 | 11,853 | D | — | — | |
| 6 | Derivative | Performance Stock Units | 2023-01-26 | M | D | 2,400 | $0.00 | 0 | D | $0.00 · — to — | 2,400 Common Stock | (F1) Each performance stock unit ("PSU") represents a contingent right to receive one share of issuer common stock upon settlement. On January 26, 2023, the reporting person received 5,940 shares of issuer common stock in settlement of performance stock units (PSUs). (F4) Vesting of the PSUs was accelerated in connection with the termination of the reporting person's employment agreement without "Good Cause". |
| 7 | Derivative | Performance Stock Units | 2023-01-26 | M | D | 1,140 | $0.00 | 0 | D | $0.00 · — to — | 1,140 Common Stock | (F1) Each performance stock unit ("PSU") represents a contingent right to receive one share of issuer common stock upon settlement. On January 26, 2023, the reporting person received 5,940 shares of issuer common stock in settlement of performance stock units (PSUs). (F4) Vesting of the PSUs was accelerated in connection with the termination of the reporting person's employment agreement without "Good Cause". |
| 8 | Derivative | Performance Stock Units | 2023-01-26 | M | D | 2,400 | $0.00 | 0 | D | $0.00 · — to — | 2,400 Common Stock | (F1) Each performance stock unit ("PSU") represents a contingent right to receive one share of issuer common stock upon settlement. On January 26, 2023, the reporting person received 5,940 shares of issuer common stock in settlement of performance stock units (PSUs). (F4) Vesting of the PSUs was accelerated in connection with the termination of the reporting person's employment agreement without "Good Cause". |